Simple Summary Outcomes for patients with advanced gastric cancer continue to be
unsatisfactory despite the inclusion of new targeted therapies in the treatment options. The …

Pancreatic cancer has traditionally been associated with a dismal prognosis, even in early
stages of the disease. In recent years, the introduction of newer generation chemotherapy …

Background Microsatellite instability-high (MSI-H) is a unique genomic status in many
cancers. However, its role in the genomic features and immunotherapy in …

Mismatch repair (MMR) testing on all new cases of colorectal cancer (CRC) has customarily
been preferably performed on surgical specimens, as more tissue is available; however …

Introduction The tumor microenvironment (TME) plays a crucial role in therapy response and
modulation of immunologic surveillance. Adjuvant immunotherapy has recently been …

Abstract Claudin-18.2 (CLDN18. 2) is a member of the tight junction protein family and is a
highly selective biomarker with often abnormal expression during the occurrence and …

Immune checkpoint blocking therapy targeting the PD‐1/PD‐L1 inhibitory signalling
pathway has produced encouraging results in the treatment of a variety of cancers …

Abstract Introduction/Background Colorectal carcinoma (CRC) is a common malignancy,
with its diverse clinical, pathological, and molecular features. The immune microenvironment …

Cutaneous angiosarcoma (CAS) is the most common type of angiosarcoma that
predominantly affects older Caucasians. The outcomes of immunotherapy in CAS are …

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of gastric cancer (GC),
which still represents the third leading cause of cancer-related death in Western countries …